Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis-Reference-Cited by-同舟云学术

Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis

Published:2013-06-24 Issue:2 Volume:57 Page:90-97
ISSN:0933-7407
Container-title:Mycoses
language:en
Short-container-title:Mycoses

Author:

Heimann Sebastian M.¹,Cornely Oliver A.¹²³⁴⁵,Vehreschild Maria J. G .T.¹⁵,Glossmann Jan¹³,Kochanek Matthias¹,Kreuzer Karl-Anton¹³,Hallek Michael¹³⁴,Vehreschild Jörg J.¹⁵

Affiliation:

1. 1st Department of Internal Medicine; University Hospital of Cologne; Cologne Germany

2. Clinical Trials Centre Cologne; ZKS Köln; University Hospital of Cologne; Cologne Germany

3. Center for Integrated Oncology Köln Bonn; CIO Köln Bonn; University Hospital of Cologne; Cologne Germany

4. Cluster of Excellence - Cellular Stress Responses in Aging-Associated Diseases; CECAD; University Hospital of Cologne; Cologne Germany

5. German Centre for Infection Research (DZIF); partner site Bonn-Cologne; Cologne Germany

Funder

German Federal Ministry of Research and Education

Publisher

Wiley

Subject

Infectious Diseases,Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/myc.12105/fullpdf

Reference38 articles.

1. The changing face of epidemiology of invasive fungal disease in Europe;Lass-Florl;Mycoses,2009

2. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study;Pagano;Haematologica,2006

3. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign;Greene;Clin Infect Dis,2007

4. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group;Pauw;Clin Infect Dis,2008

5. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia;Cornely;N Engl J Med,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cost–utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country;Journal of Hospital Infection;2024-03

2. Voriconazole prophylaxis in leukemic patients: A retrospective single-center study;Journal of Oncology Pharmacy Practice;2019-09-29

3. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals;International Journal of Infectious Diseases;2019-06

4. Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis;American Journal of Infection Control;2018-09

5. Lateral Flow Assays for the Diagnosis of Invasive Aspergillosis: Current Status;Current Fungal Infection Reports;2017-04-29